Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Mapk14b is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each.
Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets (By similarity)
The TXY motif contains the threonine and tyrosine residues whose phosphorylation activates the MAP kinases
No mutation information available.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to MAPK14, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 34
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02145468 | Acute Coronary Syndrome | A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) | PHASE3 | COMPLETED |
| NCT01393990 | Advanced Cancer | A Study of LY2228820 in Participants With Advanced Cancer | PHASE1 | COMPLETED |
| NCT00095680 | Multiple Myeloma | Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | PHASE2 | COMPLETED |
| NCT00976560 | Depressive Disorder, Major | Clinical Study to Test a New Drug to Treat Major Depression | PHASE2 | COMPLETED |
| NCT04001517 | Dementia With Lewy Bodies (DLB) | Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies | PHASE2 | COMPLETED |
| NCT00395577 | Rheumatoid Arthritis | A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 | PHASE2 | COMPLETED |
| NCT05765955 | Influenza, Human | Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses | PHASE1 | COMPLETED |
| NCT07033481 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | PHASE2 | RECRUITING |
| NCT05869669 | Dementia With Lewy Bodies | RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | PHASE2 | COMPLETED |
| NCT06815965 | Dementia With Lewy Bodies (DLB) | A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | PHASE2 | COMPLETED |